Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Coeptis Therapeutics Holdings (COEPW) over the last 4 years, with Q3 2025 value amounting to $315000.0.

  • Coeptis Therapeutics Holdings' Share-based Compensation rose 53636.36% to $315000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 8471.51%. This contributed to the annual value of $1.3 million for FY2024, which is 6993.41% down from last year.
  • According to the latest figures from Q3 2025, Coeptis Therapeutics Holdings' Share-based Compensation is $315000.0, which was up 53636.36% from $1.8 million recorded in Q2 2025.
  • Coeptis Therapeutics Holdings' 5-year Share-based Compensation high stood at $3.5 million for Q1 2022, and its period low was $49500.0 during Q3 2024.
  • For the 4-year period, Coeptis Therapeutics Holdings' Share-based Compensation averaged around $897104.1, with its median value being $541750.0 (2024).
  • As far as peak fluctuations go, Coeptis Therapeutics Holdings' Share-based Compensation crashed by 9069.2% in 2024, and later soared by 53636.36% in 2025.
  • Over the past 4 years, Coeptis Therapeutics Holdings' Share-based Compensation (Quarter) stood at $363500.0 in 2022, then rose by 15.98% to $421601.0 in 2023, then tumbled by 57.38% to $179676.0 in 2024, then skyrocketed by 75.32% to $315000.0 in 2025.
  • Its Share-based Compensation stands at $315000.0 for Q3 2025, versus $1.8 million for Q2 2025 and $597731.0 for Q1 2025.